Navigation Links
Amsterdam Molecular Therapeutics Reports Half-Year Results 2011
Date:8/24/2011

vantage of its AAV vector delivery technology for the efficient delivery of short and micro RNA to inhibit disease by RNA interference in two further pre-clinical disease models, for hypercholesterolemia and Huntington's disease. RNAi-based therapeutic strategies are considered highly promising in the industry, but so far, effective delivery has been elusive. In Huntington's disease, progress is being made quickly through in vivo studies and we anticipate proof of concept data in animal models by the end of 2011 for this indication. Two other important research projects are intended to greatly enhance the value of AMT's platform: gene expression control and re-administration.

Other Business Activities

The Supervisory Board, Management Board and other members of the management team have demonstrated their confidence in the prospects for AMT's success by taking a significant, fixed proportion of their remuneration in new AMT shares for the period from 1 July - 31 December 2011, and by making direct investments in AMT shares.

Financials

Results comparison

Total net loss for the period ended June 30, 2011 amounted to € 8.7 million, a reduction of 7% compared to the net loss for the period ended June 30, 2010 which amounted to € 9.4 million.

Other income, mainly representing grants, increased to € 1.3 million, compared to € 0.6 million in the corresponding period to 30 June 2010. This increase reflects the Company's success in securing additional non-dilutive funding towards the costs of its programs.

The main item within operating costs reflects the investment in Glybera® to support the registration process. Development of our other development projects has been reduced as we are constrained by our current resources and are focusing on the successful completion of the Glybera registration process. Research and development costs amounted to € 8.2 million for the period ended
'/>"/>

SOURCE Amsterdam Molecular Therapeutics B.V
Copyright©2010 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5 6 7 8

Related biology technology :

1. Amsterdam Molecular Therapeutics Reports Half Year Results 2008
2. Amsterdam Molecular Therapeutics Reports Full Year Results 2008
3. Amsterdam Molecular Therapeutics Reports Half Year Results 2009
4. The University of Amsterdam Joins the MetaMiner Metabolic Diseases Project
5. Amsterdam Molecular Therapeutics Reports Full Year Results 2009
6. Amsterdam Molecular Therapeutics Reports Half-Year Results 2010
7. Amsterdam Molecular Therapeutics Successfully Lowers Cholesterol In Vivo With Enhanced Novel MicroRNA AAV Gene Therapy
8. Amsterdam Molecular Therapeutics Appoints Dr. Carlos R. Camozzi as Chief Medical Officer
9. Amsterdam Molecular Therapeutics Files Glybera® European Marketing Application for Re-examination
10. Molecular sleuths track evolution through the ribosome
11. VisEn Announces Commercial Launch of IntegriSenseTM Fluorescence Molecular Imaging Agent
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/23/2013)... Ill. , May 23, 2013 Z ... providing value-added ingredients to a variety of industries, announced ... in a panel discussion at this year,s National Restaurant ... 20-21, 2013, on behalf of the Research Chefs Association.  ... for Restaurants: The Good, the Bad and the Ugly," ...
(Date:5/23/2013)... , May 23, 2013 Pressure BioSciences, Inc. ... the Company will host a teleconference to discuss its ... business update. The teleconference information is provided below: ... Eastern Daylight Time (EDT) Dial-in: (800) 875-3456 ... 607-2001 (Int,l) Passcode: VS22823 For those unable ...
(Date:5/23/2013)... 2013 Pusan National University Yangsan Hospital, ... and contract research company focused on research and ... today a publication reporting the induction of functional ... and immunotherapeutic vaccinia JX-594 (pexastimogene devacirepvec; Jennerex Inc.). ... the May 15 th , 2013 issue of ...
(Date:5/23/2013)... Bed bugs already cost Alton Housing Authority thousands. And as ... from kmov.com suggested that the said office might need to ... be of help, My Cleaning Products gave tips how to ... service. , The report, which was posted on May ... $35,000 for bed bug elimination, My Cleaning Products shared. ...
Breaking Biology Technology:Z Trim's Chef Erin Ryan sits on Expert Panel at NRA Show 2Z Trim's Chef Erin Ryan sits on Expert Panel at NRA Show 3Pressure BioSciences, Inc. to Discuss First Quarter 2013 Financial Results and Provide Business Update 2Pusan National University Announces Science Translational Medicine Publication Highlighting Landmark Demonstration of Functional Anti-Cancer Antibody Induction in Patients Following JX-594 Treatment 2Pusan National University Announces Science Translational Medicine Publication Highlighting Landmark Demonstration of Functional Anti-Cancer Antibody Induction in Patients Following JX-594 Treatment 3Bed Bug Exterminator Service Could Cost AHA $250K, My Cleaning Products Gives Tips How to Save Apartments from Costly Bed Bug Treatment 2
... 2 Accera, Inc., a biotechnology ... (CNS) diseases, today launched Axona(TM) in the United ... first-in-class medical food for the clinical dietary management ... Dispensed by prescription, it targets the metabolic deficiencies ...
... /PRNewswire-FirstCall/ - Angiotech Pharmaceuticals, Inc. (NASDAQ: ANPI ... new Senior Secured Term Loan and Revolving Credit Facility. ... agent and lender for both the Term Loan and ... draw secured term loan facility of up to $10 ...
... Inc.,(Nasdaq: BNVI ) today announced the online ... Menerba(TM) (formerly MF101) is,well tolerated, safe and effective for ... associated with menopause. , The ... safety and,efficacy of two doses of Menerba versus placebo. ...
Cached Biology Technology:Video: Accera Launches Axona(TM), First Medical Food Therapy to Help Manage Mild-to-Moderate Alzheimer's Disease 2Video: Accera Launches Axona(TM), First Medical Food Therapy to Help Manage Mild-to-Moderate Alzheimer's Disease 3Video: Accera Launches Axona(TM), First Medical Food Therapy to Help Manage Mild-to-Moderate Alzheimer's Disease 4Angiotech Pharmaceuticals, Inc. announces new Senior Secured Term Loan and Credit Facilities 2Angiotech Pharmaceuticals, Inc. announces new Senior Secured Term Loan and Credit Facilities 3Angiotech Pharmaceuticals, Inc. announces new Senior Secured Term Loan and Credit Facilities 4Bionovo Announces Publication of Positive Phase 2 Trial Results for Menerba(TM) 2Bionovo Announces Publication of Positive Phase 2 Trial Results for Menerba(TM) 3Bionovo Announces Publication of Positive Phase 2 Trial Results for Menerba(TM) 4
(Date:5/24/2013)... the immune system to combat metastatic cancer , ... destruction by the immune system. Stimulation of the immune ... are many factors that cause the immune system to ... that function to suppress the immune system response. In ... , researchers led by Ronald Levy at Stanford University ...
(Date:5/24/2013)... microRNAs (miRNAs) and other non-coding RNAs are small ... proteins. In recent years they have emerged as ... establish tissue origin for cancers of unknown primary ... for disease, but clinically tractable, diagnostic methods for ... currently available. In this issue of the ...
(Date:5/24/2013)... medication against Alzheimer,s disease, scientists have focused among other ... (A-beta). After all, it is the accumulation of A-beta that ... Starting point for the formation of A-beta is APP. Alessia ... unravel the function of APPL the fruit-fly version of ... , Alessia Soldano (VIB/KU Leuven): "We have discovered that APPL ...
Breaking Biology News(10 mins):JCI early table of contents for May 24, 2013 2JCI early table of contents for May 24, 2013 3JCI early table of contents for May 24, 2013 4JCI early table of contents for May 24, 2013 5JCI early table of contents for May 24, 2013 6JCI early table of contents for May 24, 2013 7JCI early table of contents for May 24, 2013 8A new strategy required in the search for Alzheimer's drugs? 2
... and scientific experts propose a global framework for the ... including further clinical testing In Australia. The South-Pacific ... anxiety but is restricted in some countries. Leading ... of Melbourne, Australia; Professor Rolf Teschke from Wolfgang Goethe-University, ...
... have made a significant discovery about the nature of ... Tanner, BDS, Ph.D., identified a new pathogen connected to ... wiggsiae , was present in the mouths of children ... such as Streptococcus mutans were not detected. ...
... especially for the excellence of its peacekeepers and ice ... to help countries elsewhere brace for drought, flood and ... year horizon. Within a single generation, recent studies ... by an estimated 40%, with one-third of humanity having ...
Cached Biology News:Experts propose global guidelines for safe use of Kava and new Australian study 2Forsyth team gains new insight on childhood dental disease 2Canada's role grows amid looming world water shortages in some places, more flooding in others 2Canada's role grows amid looming world water shortages in some places, more flooding in others 3Canada's role grows amid looming world water shortages in some places, more flooding in others 4Canada's role grows amid looming world water shortages in some places, more flooding in others 5Canada's role grows amid looming world water shortages in some places, more flooding in others 6Canada's role grows amid looming world water shortages in some places, more flooding in others 7
Rabbit anti-NFkB p105/p50 (Ser529) Class: Antibody Product Group: Signalling molecules and phospho-specific Antibody...
ABCA1 Immunogen: Mouse ABCA1-expressing HeLa stable transfectants. Storage: -20 C, Avoid Freeze/Thaw Cycles...
Purified Mouse anti-Hu Actopaxin (pS8) Storage Temperature: Refrigerate(2 to 8C)...
Blank Calibration Particles, 3.0-3.4 mu m 5 ml...
Biology Products: